Literature DB >> 17724457

sIL-6R: more than an agonist?

Heike Knüpfer1, Rainer Preiss.   

Abstract

On target cells, interleukin-6 (IL-6) interacts with its receptor complex consisting of the membrane-bound IL-6 receptor (IL-6R) and the signal transducing protein gp130. IL-6R can exist as a soluble protein (sIL-6R), which binds the ligand IL-6. This soluble complex can bind to gp130 on cells that lack the membrane-bound IL-6R and initiate signaling. This process is named transsignaling. The significance of transsignaling via sIL-6R is underlined by different publications and exceeds very probably the significance of the membrane-bound IL-6R. It is the general assumption that sIL-6R acts as an agonist in combination with IL-6 resulting in an enhancement of the IL-6 effects. In this article, we suppose 'non-agonistic' properties. There are several publications that give reasons to speculate that sIL-6R (a) has IL-6-antagonistic effects, (b) has orphan properties and (c) interacts with yet unknown binding partners different from IL-6. Knowledge about additional properties of sIL-6R will enlarge the biologic understanding of this molecule and might give an explanation for the sometimes contrasting effects of the cytokine IL-6.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724457     DOI: 10.1038/sj.icb.7100113

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  29 in total

Review 1.  Interleukin-6 in bone metastasis and cancer progression.

Authors:  Tasnim Ara; Yves A Declerck
Journal:  Eur J Cancer       Date:  2010-03-23       Impact factor: 9.162

2.  A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.

Authors:  Heidi V Russell; Susan G Groshen; Tasnim Ara; Yves A DeClerck; Randy Hawkins; Hollie A Jackson; Heike E Daldrup-Link; Araz Marachelian; Andrej Skerjanec; Julie R Park; Howard Katzenstein; Katherine K Matthay; Susan M Blaney; Judith G Villablanca
Journal:  Pediatr Blood Cancer       Date:  2010-11-12       Impact factor: 3.167

Review 3.  Association of longevity with TNF-α G308A and IL-6 G174C polymorphic inflammatory biomarkers in Caucasians: a meta-analysis.

Authors:  Gan-Zhong Wei; Fang Wang; Yue-Guang Zhao; Shan-Shan Li; Min-Ling Shi; Kang Gao; Ying Luo; Wen-Ru Tang
Journal:  Z Gerontol Geriatr       Date:  2016-01-11       Impact factor: 1.281

4.  Soluble interleukin-6 receptor is elevated during influenza A virus infection and mediates the IL-6 and IL-32 inflammatory cytokine burst.

Authors:  Jun Wang; Qing Wang; Tao Han; Yong-Kui Li; Sheng-Li Zhu; Fang Ao; Jian Feng; Ming-Zhen Jing; Li Wang; Lin-Bai Ye; Ying Zhu
Journal:  Cell Mol Immunol       Date:  2014-09-01       Impact factor: 11.530

5.  -174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race.

Authors:  S Mandal; F Abebe; J Chaudhary
Journal:  Genet Mol Res       Date:  2014-01-10

6.  In vitro cytokine release profile: predictive value for metastatic potential in head and neck squamous cell carcinomas.

Authors:  Omar Shkeir; Maria Athanassiou-Papaefthymiou; Martian Lapadatescu; Petros Papagerakis; Michael J Czerwinski; Carol R Bradford; Thomas E Carey; Mark E P Prince; Gregory T Wolf; Silvana Papagerakis
Journal:  Head Neck       Date:  2013-01-16       Impact factor: 3.147

7.  Altered interleukin-6 receptor, IL-6R and gp130, production and expression and decreased SOCS-3 expression in placentas from women with pre-eclampsia.

Authors:  S Zhao; Y Gu; Q Dong; R Fan; Y Wang
Journal:  Placenta       Date:  2008-11-05       Impact factor: 3.481

8.  Circulating soluble cytokine receptors and colorectal cancer risk.

Authors:  Gloria Y F Ho; Tao Wang; Siqun L Zheng; Lesley Tinker; Jianfeng Xu; Thomas E Rohan; Sylvia Wassertheil-Smoller; Xiaonan Xue; Leonard H Augenlicht; Ulrike Peters; Amanda I Phipps; Howard D Strickler; Marc J Gunter; Mary Cushman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-05       Impact factor: 4.254

Review 9.  Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance?

Authors:  Carlo Chizzolini; Jean-Michel Dayer; Pierre Miossec
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

10.  Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells.

Authors:  Frédéric R Santer; Kamilla Malinowska; Zoran Culig; Ilaria T Cavarretta
Journal:  Endocr Relat Cancer       Date:  2010-02-18       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.